Baird Medical Presents Advanced MWA Technology to UCLA Expert in China
Baird Medical (NASDAQ: BDMD) recently hosted Dr. Gary G. Tse, an interventional radiologist from UCLA Health, for a clinical visit in Guangzhou, China. The visit showcased the company's advanced microwave ablation (MWA) technology for minimally invasive thyroid treatments.
During the visit at Sun Yat-sen University Cancer Center, Dr. Tse observed multiple thyroid nodule ablation procedures using Baird Medical's MWA system. The visit also included academic discussions with Dr. Michael Mingzhao Xing from Johns Hopkins University School of Medicine, focusing on advancements in thyroid nodule management.
Baird Medical (NASDAQ: BDMD) ha recentemente ospitato il Dr. Gary G. Tse, un radiologo interventista della UCLA Health, per una visita clinica a Guangzhou, Cina. La visita ha messo in evidenza la tecnologia di ablazione a microonde (MWA) dell'azienda per trattamenti tiroidei minimamente invasivi.
Durante la visita al Centro Oncologico dell'Università Sun Yat-sen, il Dr. Tse ha osservato diverse procedure di ablazione di noduli tiroidei utilizzando il sistema MWA di Baird Medical. La visita ha incluso anche discussioni accademiche con il Dr. Michael Mingzhao Xing della Johns Hopkins University School of Medicine, incentrate sui progressi nella gestione dei noduli tiroidei.
Baird Medical (NASDAQ: BDMD) recientemente recibió al Dr. Gary G. Tse, un radiólogo intervencionista de UCLA Health, para una visita clínica en Guangzhou, China. La visita destacó la tecnología de ablación por microondas (MWA) de la empresa para tratamientos tiroideos mínimamente invasivos.
Durante la visita al Centro Oncológico de la Universidad Sun Yat-sen, el Dr. Tse observó múltiples procedimientos de ablación de nódulos tiroideos utilizando el sistema MWA de Baird Medical. La visita también incluyó discusiones académicas con el Dr. Michael Mingzhao Xing de la Escuela de Medicina de la Universidad Johns Hopkins, centrándose en los avances en la gestión de nódulos tiroideos.
Baird Medical (NASDAQ: BDMD)는 최근 UCLA Health의 중재 방사선과 의사인 Dr. Gary G. Tse를 중국 광저우에서 임상 방문으로 초청했습니다. 이 방문은 회사의 최소 침습 갑상선 치료를 위한 마이크로웨이브 절제 기술 (MWA)를 선보였습니다.
Sun Yat-sen 대학 암 센터에서 Dr. Tse는 Baird Medical의 MWA 시스템을 사용하여 여러 갑상선 결절 절제 절차를 관찰했습니다. 이 방문은 Johns Hopkins 대학교 의과대학의 Dr. Michael Mingzhao Xing과의 학술 토론도 포함되어 갑상선 결절 관리의 발전에 초점을 맞췄습니다.
Baird Medical (NASDAQ: BDMD) a récemment accueilli le Dr Gary G. Tse, un radiologue interventionnel de UCLA Health, pour une visite clinique à Guangzhou, en Chine. La visite a mis en avant la technologie d'ablation par micro-ondes (MWA) de l'entreprise pour des traitements thyroïdiens peu invasifs.
Lors de la visite au Centre de Cancérologie de l'Université Sun Yat-sen, le Dr Tse a observé plusieurs procédures d'ablation de nodules thyroïdiens utilisant le système MWA de Baird Medical. La visite a également inclus des discussions académiques avec le Dr Michael Mingzhao Xing de l'École de Médecine de l'Université Johns Hopkins, axées sur les avancées dans la gestion des nodules thyroïdiens.
Baird Medical (NASDAQ: BDMD) hat kürzlich Dr. Gary G. Tse, einen interventionellen Radiologen von UCLA Health, zu einem klinischen Besuch in Guangzhou, China, empfangen. Der Besuch stellte die Mikrowellenablationstechnologie (MWA) des Unternehmens für minimal-invasive Schilddrüsenbehandlungen vor.
Während des Besuchs am Krebszentrum der Sun Yat-sen-Universität beobachtete Dr. Tse mehrere Ablationsverfahren von Schilddrüsenknoten mit dem MWA-System von Baird Medical. Der Besuch umfasste auch akademische Diskussionen mit Dr. Michael Mingzhao Xing von der Johns Hopkins University School of Medicine, die sich auf Fortschritte im Management von Schilddrüsenknoten konzentrierten.
- Expanding global presence through partnership with prestigious UCLA Health expert
- Demonstration of MWA technology at major cancer center validates clinical application
- None.
Dr. Tse observed multiple thyroid nodule ablation procedures at Sun Yat-sen University Cancer Center, gaining valuable insights into the precision and clinical efficacy of Baird Medical's MWA system. In addition to the procedural observations, Dr. Tse participated in academic discussions with Dr. Michael Mingzhao Xing, Professor Emeritus at the Johns Hopkins University School of Medicine. Together, they explored the latest advancements and clinical outcomes in thyroid nodule management.
Dr. Tse's visit reinforces Baird Medical's commitment to fostering partnerships with leading medical experts worldwide. As the Company continues its global expansion, it remains dedicated to enhancing the accessibility and effectiveness of minimally invasive treatments for thyroid conditions.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-presents-advanced-mwa-technology-to-ucla-expert-in-china-302427339.html
SOURCE BDMD
FAQ
What was the purpose of Dr. Gary Tse's visit to Baird Medical (BDMD) in China?
Which medical centers were involved in BDMD's recent technology demonstration?
What type of medical technology is Baird Medical (BDMD) showcasing for thyroid treatment?
Where did Baird Medical (BDMD) conduct their recent clinical demonstration?
